Whitepaper: An Interview with Dr. John Rossi
Dr John Rossi is Chair and Professor of the Department of Molecular and Cellular Biology at the Beckman Research Institute of City of Hope (Duarte, CA). His research focuses on the biology and...
View ArticleBoehringer Ingelheim establishes translational research collaboration with...
"We are very pleased to sponsor the joint research programs..."
View ArticleRNAi-based therapies for the treatment of HIV
Since the discovery of RNA interference (RNAi) in 19981 and the demonstration of RNAi in mammalian cells in 20012, research into the mechanisms and applications of this pathway has moved swiftly. RNAi...
View ArticleThe evolution of RNAi technologies in the drug discovery business
In the past decade, the pharmaceutical industry has exploited the naturally occurring cellular RNAi pathway to enhance drug discovery research. The RNAi pathway, triggered by dsRNA, selectively,...
View ArticleFunctional genomics as a tool for guiding personalised cancer treatment
Improved understanding of the molecular alterations in cancer cells has fuelled the development of more specific and directed cancer therapies. However, it has become clear that response rates can be...
View ArticleRNAi screens for the identification and validation of novel targets: Current...
Recent advances in RNA interference (RNAi) technology and availability of RNAi libraries in various formats and genome coverage have impacted the direction and speed of drug target discovery and...
View ArticleUnconventional RNA interference – recent approaches to robust RNAi
RNA interference (RNAi) is now a standard tool in molecular biology. Short interfering RNAs (siRNAs) for knocking down your favourite human gene are only a couple of mouse-clicks away at your favourite...
View ArticlemicroRNA manipulation as a host-targeted antiviral therapeutic strategy
microRNAs (miRNA) are a class of non-coding RNA that regulate the precise amounts of proteins expressed in a cell at a given time. These molecules were discovered in worms in 1993 and only known to...
View ArticleTen years of siRNA – a clinical overview
In 2001, small interfering RNA (siRNA) was discovered as the mediator of RNA interference (RNAi), a transient and specific repression mechanism of protein expression1. After the pharmaceutical industry...
View ArticlePutting the ‘fun’ into functional genomics: a review of RNAi genomewide...
As RNA interference (RNAi) enters its teenage years from the first critical observations, it has now reached a multi-billion pound industry. There are few research areas that have expanded as quickly...
View Article
